Kathleen Grant, M.D.
Medical Oncologist-Hematologist
Chief, Division of Medical Oncology-Hematology
Private Practice of Medical Oncology-Hematology
California Pacific Medical Center
San Francisco, CA

Education

Undergraduate
1966
Summa cum laude, English Literature and Zoology
Univeristy of Minnesota, Minneapolis, MN

Graduate
1970
Doctor of Medicine
University of Minnesota School of Medicine
Minneapolis, MN

Postgraduate Training
1970 - 71
Intern in Medicine
Presbyterian Hospital
San Francisco, CA

1971-73
Resident in Pathology
Presbyterian Hospital, San Francisco, CA

1973-75
Resident in Internal Medicine Presbyterian Hospital, San Francisco, CA

1975 - 78
Fellow in Hematology-Oncology
University of California, San Francisco, CA

Board Certification
Board Certification in Internal Medicine, 1975
Board Certification in Hematology, 1978
Board Certification in Medical Oncology, 1979

Medical Licensure
1971 State of Minnesota
1972 State of California, (C34434)

Professional Experience
1978 - Present
Private practice of Medical Oncology and Hematology
San Francisco, CA

1978 - Present
Member of Attending Staff,
California Pacific Medical Center
San Francisco, CA

1978 - 94
Chief, Division of Oncology
Pacific Presbyterian Medical Center
San Francisco, CA

1982 - 92
Director, Adult Oncology Unit,
Pacific Presbyterian Medical Center
San Francisco, CA

1992 - Present
Member, Board of Directors, Pan Med Ltd.,
Pacific Professional Building
San Francisco, CA

1996 - Present
Member, Board of Directors, Expedition Inspiration Fund
for Breast Cancer Research

1997 - Present
Chief, Division of Hematology and Oncology
California Pacific Medical Center
San Francisco, CA

Associations

American Society of Clinical Oncology

American Society of Hematology

San Francisco Medical Association

California Medical Association

Breast Cancer Action

Medical Staff Activities
1982 - 1984
Member, Medical Staff Executive Committee
California Pacific Medical Center
San Francisco CA

1984 - 1992
Chairman, Cancer Committee
California Pacific Medical Center
San Francisco, CA

1992 - Present
Member, Cancer Committee
California Pacific Medical Center
San Francisco, CA

1992 - 2007
Chairman, Oncology Quality Improvement Subcommittee
California Pacific Medical Center
San Francisco, CA

2003 - Present
Chairman, Oncology Suppor tive Services Subcommittee
California Pacific Medical Center
San Francisco, CA

Awards and Special Activities
1979
Golden Shovel Award for Best Teacher
Pacific Presbyterian Medical Center
San Francisco, CA

1995
Team Physician Expedition inspiration, Breast Cancer
Survivors’ Climb of 23,000 ft. Mt. Aconcagua, Argentina

1995
Honored by Assembly Resolution No. 623
California Legislature
Sacramento, CA

1996
Contributor, Time-Life Videos Educations Series,
Colorectal Cancer

1996
Outstanding Researcher Award
California Pacific Medical Center
San Francisco, CA

1999
Breast Center Fund-raiser, Expedition Inspiration
Mt. Kilimanjaro, Kenya

Community Outreach
Big Sisters African American Breast Cancer Project
Sister to Sister Breast Cancer Program

Research Activities
Phase I trial of Immunotoxin (MoAb-RTA) in Colorectal Cancer.

Phase I trial of Immunotoxin (Moab - TRA) in Melanoma.

Southwest Oncology Group, National Surgical Adjuvant Breast and Bowel Project, West Bay Sutter Research Consortium

Publications

1. Grant K, Rodvien R, and Mielke CH, Jr.: “Altered Factor VIII in Acute Respiratory Failure.” Abstract #54. American Society of Hematology 19th Annual Meeting, Boston, Mass., Dec. 4-7, 1976

2. Grant K, Rodvien R, and Mielke CH: “Altered Factor VIII Complexes in Patients with Respiratory Insufficiency.” Thrombosis and Haemostasis, 40:326, 1978

3. Petz L, Gitlin J, Grant KM, Rodvien R, and Brotman M: Cimetidine-Induced Hemolytic Anemia: The Fallacy of Clinical Associations. J. Clin. Gastroent. 5:405-409, 1983

4. Ziegler JL, Bragg K, Abrams D, Beckstead J, Cogan M, Volberding P, Baer D, Wilkinson L, Rosenbaum E, Grant K, et al. “High Grade Non-Hodgkin’s Lymphoma in Patients with AIDS.” Ann. NY Acad Sci 437:412-419, 1985.

5. Schoeppel S, Hoppe R, Abrams D, Baer D, Grant K, Horning S, Wilkinson L, Zeigler J: “Hodgkin’s Disease in Homosexual Men - The San Francisco Bay Experience.” Proceedings of American Society of Clinical Oncology #9, vol 5:3, 1986.

6. Bermudez MA, Grant KM, Rodvien R: Lymphoma in a Population With or At Risk for AIDS - Single Institution Experience. Blood (supp 1) 68(5):127 abstract #363, Nov., 1986.

7. Bermudez M, Grant K, Rodvien R: Non-Hodgkin’s Lymphoma in a Population With or At Risk for Acquired Immunodeficiency Syndrome: Indications for Intensive Chemotherapy. American Journal of Medicine 86:71-76, 1989.

8. Poplin E, Fleming T, MacDonald JS, Rodvien R, Grant K, Fisher R: Amonafide Treatment of Refractory Esophageal Cancer.A Southwest Oncology Group Study, IND 11:47-51, 1993.

9. Parthasarathy A, Glaubiger D, Grant KM, Baron AD: “Treatment of Anal Carcinoma in HIV Positive Males: A Single Institution Experience”. American Society of Oncology, 2006 Gastrointestinal Cancers Symposium; abstract #640.

Bertrand Y. Tuan, M.D.
Hematologist-Oncologist
Pacific Hematology-Oncology Associates
California Pacific Medical Center
San Francisco, CA

Training and Professional Positions
1994 - Present
Physician, Pacific Hematology-Oncology Associates
California Pacific Medical Center
San Francisco, CA.

1993-1994
Emergency Room Physician
St. Luke's Hospital, New Bedford, MA
Malden Hospital, Malden, MA
New England Memorial Hospital, Stoneham, MA

Locum Tenems Hematology-Oncologyfor the practices of
Barbara Bjornson, M.D. and Roberto Mattii, M.D.,
Malden, MA.

1992-1993
Associate Physician, Divisions of Experimental Medicine and
Hematology/Oncology, Brigham and Women's Hospital
Boston, MA.

Instructor in Medicine, Harvard Medical School
Boston, MA

1989-1991
Clinical and Research Fellow in Medicine
Hematology/Oncology, Massachusetts General Hospital
Boston, MA.

1988-1989
Emergency Room Physician, Malden Hospital
Malden, MA.

1985-1988
Internship and Residency in Internal Medicine
Boston City Hospital, Boston, MA.

Education
1985
Albert Einstein College of Medicine, Bronx, N.Y.v M.D.

1981
University of California, Berkeley, CA.
A.B. in Biophysics with Honors.

Board Certifications

Medical Oncology

Hematology

Internal Medicine

Licensure and Certification

Diplomate, American Board of Intemal Medicine:

• Medical Oncology, 1993

• Hematology, 1992, 2002

• Intemal Medicine, 1988

Diplomate, National Board of Medical Examiners

Califomia Medical License No. GO78339

Academic Appointments
1992-1993
Instructor in Medicine
Harvard Medical School

1989-1992
Research Fellow in Medicine
Harvard Medical School

Hospital Appointments
1994
Medical Staff Member
Califomia Pacific Medical Center
San Francisco, CA

1993-1994
Medical Staff Member
Malden Hospital, Malden, MA.
New England Memorial Hospital, Stoneham, MA.
Whidden Hospital, Everett, MA

1992-1993
Associate Physician
Brigham and Women's Hospital

1989-1991
Clinical and Research Fellow in Medicine
Massachusetts General Hospital

Memperships

American Society of Hematology

American Society of Clinical Oncology

Research Activities
1990-1993
Hematology/Oncology Research Fellow with Thomas Stossel, M.D. and David Kwiatkowski, M.D., Ph.D. Massachusetts General Hospital and Brigham and Women's Hospital,

Study of the effects of overexpression of the actin-binding protein Gelsolin and deletion mutants of gelsolin on cellular motility and cellular transformation.

1984
Medical Student Research Associate with Karl Weisgraber, Oh. D., Gladstone Foundation Laboratories for Cardiovascular Research, University of California,
San Francisco.

Developed an assay using oligonucleotides to detect apolipoprotein E genetic polymorphisms

1981
Research Associate with Karl Weisgraber, Ph.D.
Glastone Foundation Laboratories

Analyzed Apolipoprotein B structure

1980-1981
Senior Honors Thesis Research with Alex Nichols, Ph. D.,
Department of Biophysics, University of California,

Studied the effects of dietary cholesterol on electrophoretic Patterns of baboon lipoproteins

Ari D. Baron, M.D.
Hematologist-Oncologist
Pacific Hematology-Oncology Associates
California Pacific Medical Center
San Francisco, CA,
September 1996 - Present

Associate Clinical Professor
Department of Medicine, University of California
San Francisco, CA
June 2004 - Present

Medical Director
Clinical Oncology Research Program
California Pacific Medical Center
San Francisco, CA, 12/07

Medical Director
GI Oncology Section
California Pacific Medical Center
San Francisco, CA, 12/07

Education
Wesleyan University
Middletown, CT
B.A. in English, 1984

Tufts University School of Medicine
Boston, MA, M.D., May 1990

University of California, San Francisco
Department of Medicine, San Francisco, CA
Medical Residency, June 1993.

University of California, San Francisco
Division of Hematology-Oncology, San Francisco, CA
Hematology-Oncology Fellowship
July 1994-September, 1996.

University of California, San Francisco
Department of Epidemiology and Biostatistics, San Francisco, CA
Outcomes Research and Clinical Epidemiology
August, 1996

Licenses and Certifications
California Medical license: G072619 since October 1991

Diplomate, American Board of Internal Medicine
September 1993

Diplomate, ABIM: Medical Oncology
November 1997

Principle Positions Held
Staff Physician
Veterans Administration Medical Center
San Francisco, CA
July 1993 - July 1994

Staff Physician
San Francisco General Hospital Emergency Services
San Francisco, CA
July 1993 - July 1996

Clinical Instructor
Department of Medicine, University of California,
San Francisco, CA
July 1993 - June 1994 & July 1995 ’Äì June 1997

Assistant Clinical Professor
Department of Medicine, University of California,
San Francisco, CA
June 1997 ’Äì June 2004

Clinical Associate
Department of Epidemiology & Biostatistics, UCSF
July 1995 ’Äì June 1996

Honors and Awards

Joseph Collins Foundation Grand,based on academic achievement and demonstrated interest in the arts and letters, 1988 - 1990

Alpha Omega Alpha,National Medical Honors Society,
October 1989

Julius Krevans Award for clinical excellence, Department of Medicine,
University of California, San Francisco, April 1991. Awarded to outstanding intern.

Excellence in Teaching Award, Department of Medicine,
University of California, San Francisco, 1995. Awarded to outstanding teacher among clinical fellows by medicine house staff.

Professional Affiliation
San Francisco Interns and Residents Association
1990 - 1993

Massachusetts Medical Society
1986 - Present

American College of Physicians
1993 - Present

San Francisco Medical Society
September 1996 - Present

American Society of Clinical Oncology
Active Member
July, 1996 - Present

University Service
Interdepartmental Task Force to establish disability insurance coverage for housestaff. University of California, San Francisco Medical Center, 1991.

Fellowship education committee, established to review and redesign training program. Division of Hematology-Oncology, University of California, San Francisco, Fall 1995.

Interviewer, Internal Medicine Residing Program, California Pacific Medical Center, University of California, San Francisco, 1998 - 2002.

Anticoagulation Quality Assurance: Developed guidelines and teaching tools to improve safety of anticoagulation. California Pacific Medical Center, San Francisco, 1997-1998.

Chairman, Science Committee, California Pacific Medical Center, San Francisco, CA. Develop and administer clinical research program in oncology for largest private hospital in northern California. 2001-present

Community Service
Co-founder, Student, Student Committee on Racial Awareness, Wesleyan University, Middletown, CT. Developed and led workshops on racism on campus. 1981 - 1984.

Co-founder, AIDS Education Group, Tufts University School of Medicine, Boston, MA. Developed and led workshops on AIDS education for resident advisors, Tufts undergraduate campus. Fall 1986.

Co-founder Member, Kids in Chemotherapy Support. Helped start group of Big Brothers and Sisters to support children with cancer. New England Medical Center, sBoston Floating Hospital for Children. 1987 - 1989.

Member, Board of Directors, Patient Assistance Foundation. California Pacific Medical Center, San Francisco, CA June, 2007.

Member, Board of Directors, Developing Indigenous Resources, a non-profit organization committed to health care in India. June, 2007.

Research Experience
Research Technician, Division of Cell Biopsy, Children’s Hospital, Boston, MA. Independently involved in the investigation of the structure and regulation of the acute phase response genes of the human immune system. 1984 - 1986.

Clinical Research Intern, Division of Adult Oncology, Hammersmith Hospital, London. Followed patients in Phase II clinical trial of radiolabeled monoclonal antibodies against ovarian cancer. Summer 1986.

Publications
“Sweet’s Syndrome During G-CSF Therapy.” Parks, J. Mehrotra, B., Barnett, B., Baron, A., Venook, A. Annals of Internal Medicine, 1992; 116:996-999

“Pseudomonas aeruginosa Bronchopulmonary Infection in Late HIV Disease.” Baron, A. and Hollander, H. Presented at the 8th International AIDS Conference, Amsterdam, July 1992. American Review of Respiratory Diseases, 1993; 148:992-6

“Ketoconazole Retains Activity in Advanced Prostate Cancer Patients Who Have Progressed Despite Flutamide Withdrawal.” Small, EJ., Baron, A.D., Fippin, L. Journal of Urology, 1997; 157:1204-07

“Simultaneous Anti-androgen Withdrawal and Treatment with Ketoconazole in Patients with Advanced Hormone Refractory Prostate Cancer.” Small, E.S., Baron, A.D., Bok R. ASCO Abstract # 1117, 1997. Cancer 1997; 80:1755-9

“Addition ofBevacizumab (rhuMab VEGF) to Bolus IFL in the First-Line Treatment of Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Trial.” Hurwitz, Fehrenbacher, Novotny, Car twright, Hainsworth, Heim, Berlin, Baron, Griffing, Holmgren, Ferrara, Fyfe, Rogers, Ross, Kabbinnavar New England Journal of Medicine 2004;350:2335-42.

“A Phase 2a Trial of Weekly Patupilone ( EPO 906) in Patients With Hormone- Refractory Prostate Cancer (HRPC.)” Hussain, Dipaola, Baron, Higano, Tchekmedyian, Miller, Rothermel ProcASCO 2004, Abstract # 4563. Annals of Oncology 2009 20(3):492-497.

“Influence of Hepatic Dysfunction on Safety, Tolerability and Pharmacokinetics of PTK787/ZK 222584 in Patients with Unresectable Hepatocellular Carcinoma.” Koch, Baron, Roberts, Junker, Palacay-Ramona, Masson, Laurent, Kay, Wiedenmann, Cebon. ProcASCO 2005. Abstract # 4134.

“Traztuzumab and Vinorelbine or Taxane Chemotherapy for Her2+ Metastatic Breast Cancer : the TRAVIOTA Study.” H. Burstein, A. Keshaviah, A. Baron, R. Har t, R. Lambert-Falls, P. Marcom, R. Gelman, E. Winer ProcASCO 2006, Abstract # 650, and Cancer 2007; 110: 965-972.

“A Randomized Multicenter Study to Determine the Safety and Efficacy of the Immunoconjugate SGN-15 Plus Docetaxel for the Treatment of Non-Small Cell Lung Carcinoma.” H.Ross, L. Har t, P. Swanson, M. Rarick, R. Figlin, A. Jacobs, D. McCune, A. Rosenberg, A. Baron, L. Grove, M. Thorn, D. Miller, A. Sing, J. Drachman, C. Rudin Lung Cancer 2006; 54, 69-77

“Hepatocellular Carcinoma: Current and Evolving Therapies.” Gish, R and Baron, A., IDrugs 2008 11(3): 198-203

Lectures
Prostate Cancer : Current Controversies and Advances, Medical Grand Rounds, California Pacific Medical Center, 4-97, Marin General, 12-97, Davies Medical Center, 1-98, Hawaiian Urologic Association, 1-98, John Muir Medical Center 7-98, San Francisco General Hospital 7-98, St. Mary’s Medical Center 1-00, Phoenix Urological Association, 2002, Tuscon VAMC 2002.

Lung Cancer : Update on Current Treatment, Kaiser Permanente, 12-97, Marin General Hospital 12-98, Good Samaritan Hospital, San Jose,2003, Alvarado Hospital,, San Diego 11-2006.

Hypercoagulability and Its Treatment, Medical Grand Rounds, California Pacific Medical Center 12-98, Davies Medical Center 1-99.

Breast Cancer Prevention, Medical Grand Rounds, St. Joseph’s Medical Center, Burbank, California 1-99.

Targeted Therapy in Colorectal Cancer, Medical Grand Rounds, CPMC; Burbank; Por tland; Seattle; Anchorage; Medford; Racine; 8/03- present.

Kevin B. Knopf, M.D., M.P.H.
Medical Oncologist and Hematologist
Private practice in Hematology and Oncology
Pacific Hem/Onc Associates San Francisco, CA

Director of Quality Improvement, CPMC Cancer Center

Director of Cancer Genetics, CPMC Cancer Center

Prior Employment
Private Practice/ Director of Clinical Research,
Annapolis Oncology/Hematology Center,
Annapolis, MD

Associate Staff, Oncology Section, Johns Hopkins (10%)

Education
Johns Hopkins School of Hygiene and Public Health Baltimore, MD
MPH degree granted, May 1997. Coursework in statistics and clinical trial design, health policy and management, outcomes assessment, management information systems.

University of California, San Francisco School of Medicine (UCSF) San Francisco, CA
M.D. degree granted, June 1992.

Massachusetts Institute of Technology
Cambridge, MA
B.S. in Mechanical Engineering, June 1988

Clinical Training
National Cancer Institute/National Institutes of Health
Bethesda, MD
Clinical Fellow, Medicine Branch, July 1997-2000
Research Fellow, Health Services and Economics Branch, July 1998-2000
Attending, Prostate and Ovarian Cancer Clinic 7/99 - 7/00

Evanston Hospital/Northwestern Medical School Evanston, IL
Internship and Residency in Internal Medicine, completed June 1996

Memorial Sloan Kettering Cancer Center New York, NY
Residency in Radiation Oncology, 1993-1994

Awards/Honors/Research Grants
1987 Pi Tau Sigma (National Mechanical Engineering Honor Society)

1987 Undergraduate Research Opportunities Grant - MIT

1988 Dean's Grant for Research on Fetal Heart Rate Variability - UCSF

1991 Bertram-Lobeer Memorial research Fellowship in Radiation Oncology

1998 Cancer Research Training Award
- Division of Cancer Prevention and Control (2 years)

Invited Talks at Academic Centers/International Conferences
Northwestern Medical School,
June 1999 “Quality of Life in Men with Prostate Cancer”
June 1998 “Bowel Surveillance following Colon Cancer”

American Society of Clinical Oncology May 2001 “Quality of Life in Men with Prostate Cancer Treated with LHRH agonist vs. orchiectomy”

Grand Rounds VA West Virginia, May 2006 “Update on Colon and Rectal Cancer”

Grand Rounds Urology Dept. George Washington School of Medicine, 7/06 ’ÄúUpdate on Prostate Cancer’Äù

Grand Rounds, California Pacific Medical Center 9/07 ’ÄúCurrent Controversies in Lung Cancer’Äù

Professional Organizations

American Society for Clinical Oncology

American Society of Hematology

American College of Physicians

Reviewer - Journal of Supportive Oncology, Journal of Clinical Oncology, SEER special studies

Hospital and Cancer Committees
Anne Arundel Medical Center Annapolis, Maryland
Director of Clinical Research, DeCesaris Cancer Institute

Chairman, Institutional Review Board 2002-2006

Clinical Trial Advisory Committee 2001-

Cancer Committee 2000-

Quality Management Committee 2002 -

Colorectal Cancer Prevention Task Force, Member

Prostate Cancer Prevention Task Force, Member

Developer and Moderator; Colon/Rectal Cancer Support Group

Developer and Moderator, Genitourinary Tumor Board

Frequent speaker to community and physician groups

Leukemia and Lymphoma Society, Baltimore chapter
Patient Services Committee

California Pacific Medical Center
Chair, Cancer Quality Committee 2007-
Member, Cancer Committee 2007-
Member, Nutrition Committee 2008 ’Äì

American Society of Clinical Oncology
Quality Oncology Project Initiative, Beta Member

Abstracts
Cheal EJ, Lott KC, Edwards WT, Knopf KB, and Hayes WC. Finite element modeling of failure processes in the skeleton. Orthopedic Biomechanics Laboratory, Department of Orthopedic Surgery, Charles A. Dana Research Institute, Harvard Medical School and MIT, Beth Israel Hospital, Boston, MA 02215, IEEEE Proceedings 1997

Knopf KB, Parer JT, Parer WJ, Gunn AJ, Williams CE, Gluckman PD (Intro by JM Roberts). A Comparison of visual assessment with mathematical indices of long and short term fetal heart rate variability. Dept Ob/Gyn and CVRI, Univ of Cal SF, Univ of Auckland NZ, Oral Presentation at American Federation for Clinical Resarch, Spring 1990, Carmel, California

Uhl V, Castro JR, Knopf K, and Phillips T. Heavy charged particle irradiation of bone sarcoma. International Journal of Radiation Oncology, Biology and Physics, Proceedings of the 33d Annual ASTRO Meeting 1991;21;Supp 1:1656-1657

Knop R, Shevrin D, Knopf K, et al. Pilot study of low dose weekly mitoxantrone in widely metastatic hormone refractory prostate cancer (HPRC). Proceedings of the American Society of Clinical Oncology 1993

Minsky B, Conti J, Huang Y, and Knopf K. Relationship of acute gastrointestinal (GI) toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. Proceedings of the American Society for Clinical Oncology 1995; 14:189

Knopf K, Brown M, and Kohn EC. Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer 1980-1997. Poster at the American Society of Clinical Oncology, 1998

Dahut W, Dyer V, P Arlen, Knopf K, et al. A randomized phase II trial of ketoconazole (KT) and alendronate (AL) versus high dose ketoconazole in androgen independent metastatic prostate cancer. American Urological Association Meeting, 2000, and Proceedings of the American Society of Clinical Oncology, 2001

Knopf KB, Warren JL, Feuer F and Brown M. Bowel Surveillance Patterns Following a Diagnosis of Colorectal Cancer in Medicare Beneficiaries. Proceedings of the American Society of Clinical Oncology, 2000 Poster Discussion

Knopf KB, Potosky AL, Clegg LX et al. Health Outcomes Following Primary Androgen Therapy in a Population-Based Cohort. Proceedings of the American Society of Clinical Oncology, 2001 Oral Presentation

Kiebert W, Knerer G, Liu H-T, Shih T, Brown R, Knopf K. Cost-Utility Analysis of a Randomized Clinical Trial comparing Docetaxel and Doxorubicin vs. Doxorubicin and Cyclophosphamide as first line chemotherapy for metastatic breast cancer. Proceedings of the American Society of Clinical Oncology, 2001

de Lissovoy G , Cassard SD, Knopf KB, Ciesla GN, Heyes A, and Silberman C. Duration and cost of treatment for stage IIIb-IV non-small cell lung cancer (NSCLC) patients receiving chemotherapy. Proceedings of the American Society of Clinical Oncology, 2002 231b.

Ellison GL, Brown ML, Warren JL and Knopf KB. Racial and ethnic differences in bowel surveillance procedures following colorectal cancer surgery with curative intent. Annals of Epidemiology 2002; 12(7):515

Mahedevia P, Baran RW, Knopf KB, Coop A. Cost Savings of Switching from IV to Oral 5-HT3 Antagonists for Prevention of Acute Chemotherapy Induced Nausea and Vomiting (CINV). American Managed Care Pharmacy Annual Meeting 2004

Yabroff KR, Warren JL, Davis WW, Knopf K, Brown ML. Patient time costs for breast, colorectal, and lung cancer care. Presented at International Health Economics Association meeting 2005

Luo W, Nordstrom B, Ranganathan G, Linz H, Stokes M, Ross S, Knopf K. Adherence to guidelines for use of erythropoiesis stimulating proteins in patients with chemotherapy-induced anemia: Trends from electronic medical records. Submitted, American Society of Clinical Oncology 2007

Stokes M, Muelenbein C, Marciniak M, Faries D, Montabar S, Beusching D, Gillespie T, LipscombJ, Knopf K. Costs Associated with Neutropenia in Elderly Patients treated first-line for Advanced Non-Small Cell Lung Cancer. Oral Presentation at ISPOR 2008

K. Knopf, J Lipscomb, T Gillespie, M Stokes, C Muehlenbein, D Faries, M Marciniak, S Motabar, D Buesching. Impact of neutropenia on chemotherapy administration in elderly patients with advanced Non-small Cell Lung Cancer (NSCLC). Poster at American Society of Clinical Oncology 2008

Danese M, Griffiths R, Gleeson M, and Knopf K. Validating the Follicular Lymphoma International Prognostic Index (FLI) Using SEER-Medicare claims. Data. Oral Presentation, American Society of Hematology 2008

Griffiths R, Danese M, Gleeson and Knopf K. Patterns of Chemotherapy/Immontherapy and survival in Mantle Cell Lymphoma: Evidence from SEER-Medicare. Abstract, American Society of Hematology 2008

Danese M, Lalla D, Doan Q and Knopf K. Estimating Recurrences Prevented by using trastuzumab in Stage I-3 HER2/neu Positive (HER2+) Breast Cancer in the United States. Poster presentation, San Antonio Breast Conference 2008

Lalla D, Danese M, Doan Q, Brammer M and Knopf, K. Total Societal Costs Attributable to the Prevention of Recurrent HER2+ Breast Cancer. Poster Presentation, San Antonio Breast Conference 2008

Stephens R, Knopf K. Off Label Use of Oncology Drugs in a Community Oncology EMR Databse. Poster Presentation, ISPOR May, 2009

Lindquist K, Danese M, Knopf K, Mikhael J. Mortality and hospitalization in myelodysplastic syndrome (MDS) using the SEER-Medicare linked database. Poster Presentation, American Society of Clinical Oncology 2009

Patterns and Outcomes of Initial Systemic Therapy in Elderly Patients Diagnosed with CLL in the United States: Evidence from SEER-Medicare. Poster Presentation, XIII International Workshop on CLL, 2009

Two abstracts submitted to ASCO 2010 on Lymphoma

Textbook Chapters
Knopf KB and Dahut W. “Prostate Cancer”

Knopf KB and Kohn E. “Ovarian Cancer”

Knopf KB. “Hematopoietic Growth Factors”

Chapters in Bethesda Handbook of Oncology Lippincott Press, 2000. 2nd Edition published 2002

PDQ Statement on Prevention of Oral Cancer, 4/99.

Brawley O and Knopf KB. Chapter: Cancer in Special Populations. Haskell Textbook of Oncology 6th edition, 2000

Knopf KB, Brawley OW, and Pluda J. Chapter: AIDS and Women. Principles and Practice of Gynecologic-Oncology, Third Edition. Edited by W.J. Hoskins, C.A. Perez, and R.C. Young. Lippincott-Raven, 2000

Brown ML, Knopf KB, Marcus S and Lipscomb J. Economic Analysis and Clinical Research. Principles and Practices of Clinical Research, First Edition. Edited by Gallin J 2002

Papers
Knopf K, Parer JT, Espinoza MI, et al. Comparison of mathematical indices of fetal heart rate variability with visual assessment in the human and sheep. Journal of Developmental Physiology 1991;16:367-72

Uhl V, Castro JR, Knopf K, et al. Preliminary results in heavy charged particle irradiation of bone sarcoma. International Journal of Radiation Oncology, Biology and Physics 1992;24;4:755-759

Minsky BD, Conti JA, Huang Y, and Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. Journal of Clinical Oncology 1995;13;6:1409-1416

VonRoenn JH and Knopf K. Anorexia/Cachexia in patients with HIV: lessons for the Oncologist. Oncology 1996;10;7:1049-1056

Knopf KB and Locker GY. Hodgkin's disease and HIV infection [Letter], New England Journal of Medicine 1995;333;1:65-66

Brawley OW, Knopf K, and Merrill R. The epidemiology of prostate cancer part I: descriptive epidemiology. Seminars in Urologic Oncology 1998;14:187-192

Brawley OW, Knopf K, and Thompson I. The epidemiology of prostate cancer part II: the risk factors. Seminars in Urologic Oncology 1998;14:193-201

Brown ML and Knopf KB. Is colorectal cancer screening really cost-effective? Primary Care and Cancer 1999;19:15-21

Knopf KB. Book Review: Recent results in cancer research: Assessing the economic value of anticancer therapies. Journal of the National Cancer Institute 1999;91:1248-1249

Knopf KB, Warren JL, Feuer EJ, and Brown ML. Bowel Surveillance Patterns Following A Diagnosis of Colorectal Cancer in Medicare Beneficiaries. J Gastrointestinal Endoscopy, 2001:54:563-71

Dixon SC, Knopf KB and Figg WD. The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents. Pharmacological Reviews 53:73-91, 2001

Potosky AL, Knopf K, Clegg LX, et al. Quality-of-Life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. J Clin Oncol 2001;19:3750-3757

Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS and Knopf KB. Utility of the SEER-Medicare Data to Identify Chemotherapy Use. Medical Care, Vol 40 (8) IV-55 to 61, 2002

Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R. Patterns of care for the treatment of bladder cancer. J Urology 2003;169:1697-1701

Ellison GL, Warren JL, Knopf KB and Brown ML. Racial Differences in the receipt of Bowel Surveillance Following Potentially Curative Colorectal Cancer Surgery. Health Services Research 2003;38(6):1885-1904

Mariotto A, Warren J, Knopf K and Feuer E. The Prevalence of Colorectal Cancer Patients under Care in the United States. Cancer 2003;98:1253-1251

Yabroff R, Warren J, Knopf K, Davis WW, Brown ML. Estimating Patient Time Costs Associated with Colorectal Cancer Care. Medical Care 2005;43(7): 640-648

L. Clark Paramore; Simu K. Thomas; Kevin B. Knopf; Lael S. Cragin; Kathy H. Fraeman. Estimating Costs of Care for Patients with Newly Diagnosed Metastatic Colorectal Cancer. Clinical Colorectal Cancer 6(1):52-58, 2006

Knopf K. Recent Developments in Head and Neck Cancer: The Role of Cetuximab. Community Oncology 3(12) 4-5. December 2006

Knopf K. Another Step Forward in Renal Cell Carcinoma. Community Oncology 4(9):478-479, August 2007

Knopf K and Hutton J. Value and Use of Economic Evaluation in Oncology Journal of Clinical Oncology 2007 25(35): 5666-5667

Luo W, Nordstrom BL, Fraeman K, Nordyke R, Ranganathan G, Linz HE, Winterkorn A, Stokes M, Ross SD and Knopf K. Adherence to guidelines for use of erythropoeisis stimulating agents in patients with chemotherapyinduced anemia: trends from electronic medical records. Clinical Therapeutics 2008 30(12):2423-2435

Stokes ME, Muelenbein CE, Marciniak M, Faries DE, Motabaar S, Gillespie TW, Lipscomb JE, Knopf K and Beusching DP. Neutropenia Related Costs in Patients treated with first-line chemotherapy for advanced non-small cell carcinoma of the lung. American Journal of Managed Care Pharmacy, 2009 15(8), 669-82

Waller J, Moretto J, and Knopf K. Multiple significant bortezomib-related toxicities in one patient: case report and literature review. Clinical Lymphoma and Leukemia October 2009

Treatment Patterns and Survival in Medicare Patients Diagnosed with Follicular Lymphoma. Accepted, The Oncologist 2010

Danese MD, Lalla D, Brammer M, Doan Q, Knopf K. Estimating Recurrences prevented from using Trastuzumab in HER2/neu positive adjuvant breast cancer in the United States. Accepted, Cancer 2010

Manuscripts in preparation:
1. Chronic Lymphocytic Leukemia Survival Trends 1998-2004

2. Factors Influencing Time to Initiation of Treatment in Older Patients with Diffuse Large B-Cell Lymphoma

Ongoing Blog on Breast Cancer
www.mybreastcancernetwork.com